Table Graph
   

remdesivir - versus potential COVID-19 treatments - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.10 [0.49, 2.45]< 10%1 study (1/-)40.8 %NAnot evaluable crucial-
clinical deterioration 0.95 [0.55, 1.64]< 10%1 study (1/-)57.3 %NAnot evaluable important-
clinical improvement 1.23 [0.87, 1.74]> 10%1 study (1/-)87.7 %NAnot evaluable important-
clinical improvement (14-day) 1.21 [0.64, 2.28]> 10%1 study (1/-)71.9 %NAnot evaluable important-
clinical improvement (28-day) 1.37 [0.79, 2.39]> 10%1 study (1/-)86.8 %NAnot evaluable important-
clinical improvement (7-day) 0.99 [0.18, 5.51]> 10%1 study (1/-)49.4 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.23 [0.87, 1.74]> 10%1 study (1/-)87.7 %NAnot evaluable important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
serious adverse events 0.64 [0.33, 1.23]< 10%1 study (1/-)91.0 %NAnot evaluable important-
deep vein thrombosis 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
elevated liver enzymes 0.36 [0.13, 1.01]< 10%1 study (1/-)97.3 %NAnot evaluable non important-
hyperbilirubinemia 1.09 [0.42, 2.79]< 10%1 study (1/-)43.1 %NAnot evaluable non important-
pulmonary embolism 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
renal impairment 1.01 [0.03, 30.33]< 10%1 study (1/-)49.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons